Johnson & Johnson vs. Rallybio Corporation Common Stock
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| JNJ | RLYB | |
|---|---|---|
| Market Cap | $614.36 billion | $85.65 million |
| Revenue (TTM) | $97.93 billion | $858,000 |
| Net Income (TTM) | $21.04 billion | $-7,817,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | RLYB | |
|---|---|---|
| P/E Ratio | 29.88 | — |
| Price / Book | 7.23 | 1.70 |
| Price / Sales | 6.27 | 99.83 |
JNJ and RLYB split the valuation factors evenly.
Profitability
| JNJ | RLYB | |
|---|---|---|
| Net Margin | 21.48% | -911.07% |
| Return on Equity | 24.76% | -15.55% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | RLYB | |
|---|---|---|
| Dividend Yield | 2.08% | — |
| Payout Ratio | 62.18 | — |
JNJ and RLYB split the dividend factors evenly.
Risk & Sentiment
| JNJ | RLYB | |
|---|---|---|
| Short Interest | 0.67% | 0.02% |
RLYB leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, RLYB overview, RLYB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.